Literature DB >> 15818710

The incidence and natural history of Raynaud's phenomenon in the community.

Lisa G Suter1, Joanne M Murabito, David T Felson, Liana Fraenkel.   

Abstract

OBJECTIVE: Raynaud's phenomenon (RP) is a common disorder, yet its incidence and natural history are unknown. Our objective was to determine the incidence and natural history of RP not associated with a connective tissue disease in a large, community-based population.
METHODS: Using serial examinations of the Framingham Heart Study offspring cohort, we collected data regarding RP symptoms for 717 women and 641 men over a 7-year period. We used validated criteria for RP classification and categorized participants as having incident, persistent, or remitted RP. We performed sex-specific analyses of RP status by age, body mass index, vibratory tool use, season of examination, state of residence, use of antihypertensive medications, and smoking status.
RESULTS: The mean +/- SD age of participants was 53.5 +/- 10 years. The incidence of RP was 2.2% in women (n = 14) and 1.5% in men (n = 9). Of the 78 women and 50 men who had RP at baseline, 36% of women (n = 28) and 36% of men (n = 18) had persistent RP. RP remitted in 64% of women (n = 50) and 64% of men (n = 32), with 41 women and 25 men meeting no or only 1 RP criterion at followup. RP episodes were infrequent and rarely interfered with daily activities.
CONCLUSION: This is the first prospective study to determine the incidence and natural history of RP in a community-based cohort. Our data demonstrate that RP not associated with a connective tissue disease is frequently a transient phenomenon and rarely interferes with daily activities.

Entities:  

Mesh:

Year:  2005        PMID: 15818710     DOI: 10.1002/art.20988

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  32 in total

Review 1.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

Review 2.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

3.  [Primary and secondary Raynaud's phenomenon].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

4.  Raynaud's phenomenon in Northern Sweden: a population-based nested case-control study.

Authors:  Albin Stjernbrandt; Hans Pettersson; Ingrid Liljelind; Tohr Nilsson; Jens Wahlström
Journal:  Rheumatol Int       Date:  2018-08-20       Impact factor: 2.631

5.  Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials.

Authors:  Heather Gladue; Paul Maranian; Harold E Paulus; Dinesh Khanna
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-04       Impact factor: 4.794

Review 6.  Management of Raynaud's phenomenon and digital ischemia.

Authors:  Ariane L Herrick
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

Review 7.  Peripheral vasoconstriction induced by β-adrenoceptor blockers: a systematic review and a network meta-analysis.

Authors:  Charles Khouri; Thomas Jouve; Sophie Blaise; Patrick Carpentier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-05-31       Impact factor: 4.335

Review 8.  A Review of Raynaud's Disease.

Authors:  Katherine K Temprano
Journal:  Mo Med       Date:  2016 Mar-Apr

Review 9.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

10.  The alpha2C-adrenoceptor deletion322-325 variant and cold-induced vasoconstriction.

Authors:  Eitan A Friedman; Paul A Harris; Alastair J J Wood; C Michael Stein; Daniel Kurnik
Journal:  Clin Auton Res       Date:  2009-05-15       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.